BioCentury
ARTICLE | Distillery Therapeutics

Cancer

June 14, 2017 4:55 PM UTC

Mouse studies suggest inhibiting HspA5 could help treat pancreatic ductal adenocarcinoma (PDAC). In male and female mouse models of PDAC, HspA5 knockdown decreased number of ducts with acinar-to-ductal metaplasia, Pancreatic Intraepithelial Neoplasias or PDAC tumors and increased survival of male mice compared with normal HspA5 expression. Next steps include identifying HspA5 inhibitors.

Intezyne Technologies Inc. has IT-139, a transferrin-targeted ruthenium-based small molecule that down-regulates HspA5, in Phase I/II testing for cancer and Phase I testing for advanced refractory solid tumors...